Studio Pivotale sul Dispositivo Antibiotico per Osteomielite degli Arti - Genex con Gentamicina. (ADOPT GG)
Uno studio clinico multicentrico, a braccio singolo, controllato storicamente e fondamentale, per valutare la sicurezza e l'efficacia di Genex G come parte del trattamento chirurgico dell'osteomielite degli arti.
The purpose of this trial is to determine if genex with gentamicin (genex G) an antibiotic loaded bone void filler, works to treat and is a safe option as part of the surgical treatment of osteomyelitis in the extremities.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This trial is a multi-center, single arm, historically controlled, pivotal device study.
All participants diagnosed with osteomyelitis of the extremities (Cierny-Mader Classification grades I-IV) can be considered. All participants will undergo surgical debridement and will receive genex with gentamicin (genex G) antibiotic loaded bone void filler as part of the surgical treatment of osteomyelitis of the extremities. Participants will receive antibiotics per site specific requirements as clinically indicated. All participants will be followed up for 24 Months.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Keira Watts, PHD
- Numero di telefono: +44 (0)1782 338580
- Email: clinicaltrials@biocomposites.com
Backup dei contatti dello studio
- Nome: Simal Trikam
- Email: strikam@mcra.com
Luoghi di studio
-
-
California
-
San Diego, California, Stati Uniti, 92104
- Non ancora reclutamento
- North Park Podiatry
-
Investigatore principale:
- Trent Brookshier, DPM
-
Contatto:
- Trent Brookshier, DPM
- Email: trentbrookshier@gmail.com
-
Contatto:
- Vanessa Enriquez
- Email: venriquez.npp@gmail.com
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46278
- Reclutamento
- OrthoIndy
-
Contatto:
- Melanie Glover
- Email: mglover@orthoindy.com
-
Contatto:
- Kimberly Fitzpatrick
- Email: kifitzpatrick@orthoindy.com
-
Investigatore principale:
- Sandeep Soin, MD
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21215
- Reclutamento
- Sinai Hospital Baltimore
-
Investigatore principale:
- Janet Conway, MD
-
Contatto:
- Nathaniel Helwig
- Email: nhelwig@lifebridgehealth.org
-
Contatto:
- Sara Orem
- Email: sorem@lifebridgehealth.org
-
-
New Jersey
-
Oradell, New Jersey, Stati Uniti, 07649
- Reclutamento
- Curalta Clinical Trials
-
Contatto:
- Radhika Gajera
- Email: rgajera@curalta.com
-
Investigatore principale:
- Vincent Giacalone, DPM
-
Contatto:
- Harrison Miller
- Email: hmiller@curalta.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patient with osteomyelitis of the extremities, who have failed antibiotic therapy and are requiring surgical intervention (unresolved osteomyelitis), Cierny-Mader classification of osteomyelitis grades I-IV. Patients presenting with Cierny-Mader grades I-II will be required to have a defect created as part of debridement surgery
-
Patients at least 18 years of age *1
-
Patient willing and able to provide written informed consent
-
Patient geographically stable and able to comply with the required follow-up visits and testing schedule as assessed by the investigator
-
Ability to achieve adequate surgical soft tissue coverage of the wound (primary tissue closure or surgical reconstruction including local and free soft tissue transfer)
- 1 Patients between 18 and 22 years of age require confirmation of skeletal maturity as validated by radiographs of the bone to be treated.
Exclusion Criteria:
- Patients diagnosed with acute osteomyelitis
- Patients with Cierny-Mader grades I-II who are unable to have a defect created during debridement surgery
- Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/dL (309umol/L) or being treated with dialysis
- Participants with a terminal or palliative diagnosis (e.g. terminal cancer diagnosis) deemed to have less than 1 year life expectancy by their health care team
- Uncontrolled diabetes mellitus (hemoglobin A1c levels >10%)
- Pre-existing calcium metabolism disorder
- Women who are pregnant or breastfeeding or planning on becoming pregnant during the study (a pregnancy test will be done in women of childbearing potential at screening and on the day of surgery)
- History of hypersensitivity or contraindication to the investigational device or any of its ingredients (calcium phosphate, β-tricalcium phosphate, and aminoglycoside antibiotics)
- Participation in an investigational drug/device study (within the last 60 days) or prior enrolment to the ADOPT GG study
- Clinically significant or unstable medical or surgical condition that in the investigators opinion may preclude safe and complete study participation (for example patients medically unfit for surgery, general anesthesia, or any risk of significant blood loss resulting in significant risk to loss of life)
- Current untreated malignant neoplasm(s), or current treatment with radiation therapy or chemotherapy
- Current or recent history (within last 2 years) of active substance abuse (e.g. recreational drugs, narcotics, or alcohol) that meets DSM-5 severe criteria
- Currently incarcerated
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Single Arm
Participants will receive genex with Gentamicin, an antibiotic loaded bone void filler that supports bone healing, as part of the surgical treatment of osteomyelitis of the extremities. |
genex with gentamicin will be implanted during debridement surgery |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
No further requirement for antibiotic treatment due to persisting symptoms of infection at the index site (i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post surgery.
Lasso di tempo: Month 12
|
Further requirement for antibiotic treatment due to persisting symptoms of infection at the site of treatment will be assessed at Month 12. |
Month 12
|
|
No further surgical interventions required due to infection at the index site.
Lasso di tempo: Month 12
|
Need for further surgical interventions required due to infection at the index site will be assessed at Month 12. |
Month 12
|
|
No recurrence of sinus formation at the index site.
Lasso di tempo: Month 12
|
Recurrence of sinus formation at the index site will be assessed by a non-contrast CT scan at week 2 & Month 12. Clinical endpoint assessments will also be used to measure this at post operative follow-up visits and will be assessed at Month 12. |
Month 12
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
No additional requirement for antibiotic treatment due to persisting symptoms of infection at the treatment site, i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post-surgery.
Lasso di tempo: Month 24
|
Further requirement for antibiotic treatment due to persisting symptoms of infection at the site of treatment will be assessed at Month 24. |
Month 24
|
|
No radiographic evidence of post op fractures.
Lasso di tempo: Month 24
|
Radiographic evidence of post-operative fractures will be evidenced by X-ray & CT evaluations and assessed at Month 24. |
Month 24
|
|
Radiographic evidence of new bone healing.
Lasso di tempo: Month 24
|
Radiographic evidence of new bone healing will be evidenced by X-ray and CT evaluations and assessed at Month 24. |
Month 24
|
|
No recurrence of sinus formation at the treatment site.
Lasso di tempo: Month 24
|
Recurrence of sinus formation at the index site will be assessed by contrast enhanced CT evaluation and Clinical endpoint assessments measured at Month 24. |
Month 24
|
|
No secondary surgical interventions (SSI's) related to the investigational treatment.
Lasso di tempo: Month 24
|
Secondary Surgical interventions (SSI's) related to the investigational treatment will be assessed at Month 24. |
Month 24
|
|
No serious adverse events that are definitely related to genex G.
Lasso di tempo: Month 24
|
Serious adverse events that are definitely related to genex G will be assessed at Month 24. |
Month 24
|
|
Radiographic Evidence of new bone formation and product reabsorption.
Lasso di tempo: Month 24
|
Radiographic evidence of new bone formation and product reabsorption will be evidenced by X-ray and CT evaluations during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Infection resolution evaluated by radiographic assessment and clinical endpoints.
Lasso di tempo: Month 24
|
Radiographic evidence of infection resolution will be evidenced by contrast enhanced CT evaluations and clinical endpoint assessments assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Adverse events including wound problems, reaction to combination product, fracture at treatment site.
Lasso di tempo: Month 24
|
Adverse events including wound problems, reaction to combination product, fracture at treatment site will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Secondary Surgical Interventions (SSI's)
Lasso di tempo: Month 24
|
Number of Secondary Surgical Interventions (SSI's) will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Number of participants discontinuing therapy prematurely due to a device related event.
Lasso di tempo: Month 24
|
Number of participants discontinuing therapy prematurely due to a device related event will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Number of hospitalisations/re-hospitalisation due to treatment site Osteomyelitis.
Lasso di tempo: Month 24
|
Number of hospitalisations/re-hospitalisation due to treatment site Osteomyelitis. |
Month 24
|
|
Quality of Life EQ-5D-5L
Lasso di tempo: Month 24
|
Impact on the participants Quality of Life will be measured by the EQ-5D-5L during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Keira Watts, PHD, Biocomposites Ltd
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 201924
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .